tradingview.comOct 16$PBAM

Private Bancorp of America, Inc. (PBAM) Q3 Net Income $11.4M, EPS $1.97

Private Bancorp of America reported Q3 2026 net income of $11.4M, or $1.97 per diluted share, down from Q2 but up from Q3 2025. Net interest margin was 5.05%, and deposits increased by $31.8M. The company recently uplisted to NASDAQ.

Original reporting

tradingview.com

Published Oct 16, 2026, 12:00 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Oct 16, 2026, 12:19 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

Private Bancorp of America, Inc. (PBAM) Q3 Net Income $11.4M, EPS $1.97 — source image — Source · tradingview.com

Decision brief

The 30-second read

$PBAMNeutralMed

Why it matters

Earnings provide the first detailed financial snapshot post-uplisting, highlighting operational trends.

Market read

The earnings release offers fresh data for traders assessing small-cap banking stocks.

What to watch

Potential upside from upcoming mid-cycle catalyst if NIM stabilizes next quarter.

Relevance 7/10Novelty 7/10Timing: today

Background

Private Bancorp of America recently uplisted to NASDAQ, positioning itself for greater visibility.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$PBAMNeutralMedium confidence

Context

Q3 2026 earnings released: net income $11.4M, EPS $1.97, NIM 5.05%, deposits up $31.8M.

Expected impact

potential modest downside as NIM compression offsets deposit growth

Evidence & confidence

Quarterly results are the first report; small cap scale limits move, but mixed signals suggest limited upside.

Market effects

Sector

Banking sector may see slight pressure from NIM compression trends.

Regional

US regional banks could be marginally affected.

Global

Limited; impact confined to niche community banks.

Counterpoint

What could challenge this read

Despite QoQ dip, deposit growth could support share price if NIM stabilizes.

Key entities

company
Private Bancorp of America, Inc.
US regional bank reporting Q3 2026 results.

Read at source ← All news

$PBAMMedAI 8/10

Private Bancorp of America GAAP EPS of $1.97 misses by $0.10, revenue of $35.5M beats by $0.43M (NASDAQ:PBAM)

Private Bancorp of America reported Q3 GAAP EPS of $1.97, missing estimates by $0.10, while revenue of $35.5M exceeded expectations by $0.43M, up 12.7% year-over-year, according to the company.

seekingalpha.comOct 16

$PBAMMed

Private Bancorp of America, Inc. Announces Strong Net Income for Third Quarter 2026

Private Bancorp of America, Inc. (PBAM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE Private Bancorp of America, Inc. Announces Strong Net Income for Third Quarter 2026 Third Quarter 2026 Highlights • Net income for the third quarter of 2026 was $11.4 million, compared to $13.1 million in the prior quarter and $9.7 million in th

SEC EDGAR 8-KOct 16

$PTHSMed

Pelthos (PTHS) Q3 2026 Earnings Call Transcript

Pelthos (PTHS) reported Q3 2026 net revenue of $15.2M, up 114% YoY, with Zelsuvmi treating 31,000 patients. Formulary coverage expanded to 70% of commercial lives. The company announced a deal with Castle Creek Biosciences, aiming to leverage synergies in dermatology and cell/gene therapy markets. Xepi and Xeglyze launches are planned for 2027.

finance.yahoo.comNov 13

$BMNRMedAI 8/10

Bitmine’s ($BMNR) $6.3 Billion Loss Highlights Overall Risks for Strategy ($MSTR) and Other Treasury Firms as MSCI Tightens Rules

Bitmine Immersion Technologies (BMNR) reported a $6.3B net loss for fiscal 2026, driven by $6.23B in unrealized losses on digital-asset holdings, primarily ether. The company held 5.9M ether tokens and 211 bitcoin at year-end. Operating revenue was $125M, with staking contributing 97%. MSCI's updated index rules may impact BMNR and other crypto-focused treasury firms, including Strategy (MSTR).

crowdfundinsider.comNov 13

Med

Cellectis (ALCLS) Reports $101.1M Nine-Month Net Loss; Cash Runway Into H2 2028

Cellectis reported a $101.1M net loss for the nine months ended September 30, 2026, up from $41.3M in 2025, with $149M in cash and deposits. The company expects funding to last into the second half of 2028. This follows a strategic shift to in vivo gene editing and restructuring.

tradingview.comNov 13

HighAI 8/10

Merck KGaA Earnings Call Signals Stronger Growth Ahead

Merck KGaA (MKKGY) reported Q3 earnings with accelerated growth, raised full-year guidance, and announced strategic investments. Key highlights include 5.1% organic sales growth, EUR 1.66B operating cash flow, and plans to acquire Silence Therapeutics. Management emphasized growth in biomanufacturing, semiconductors, and rare diseases, while noting Mavenclad's declining sales and softer demand in consumer electronics.

tipranks.comNov 13